The government is now operating in accordance with the Guidance on Caretaker Conventions, pending the outcome of the 2025 federal election.
FASENRA AstraZeneca Pty Ltd
Product name
FASENRA
Sponsor
Accepted date
Feb-2024
Active ingredients
benralizumab
Proposed indication
FASENRA is indicated for the treatment of adult patients with eosinophilic granulomatosis with polyangiitis.
Application type
C (new indication)
Publication date
Feb-2024